A prospective observational study of temporal change in pulmonary function during epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with non-small cell lung carcinoma.

A prospective observational study of temporal change in pulmonary function during epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with non-small cell lung carcinoma. - A prospective observational study of temporal change in pulmonary function during EGFR-TKI treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015569

Enrollment

Registered

2014-11-01

Start date

2014-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with non-small cell lung cancer who are going to receive EGFR-TKI treatment 2) Chemotherapy-naive patients or patients who have not received any chemotherapies more than 1 month 3) Patients of 20 years of age or older 4) Patients with life expectancy >= 3 months 5) Patients who offer the documented agreement to the study

Exclusion criteria

Exclusion criteria: 1) History of thoracic radiotherapy

Design outcomes

Primary

Measure	Time frame
The rate of change in DLCO from baseline after EGFR-TKI administration	—

Secondary

Measure	Time frame
(1) Other spirometric parameters change (FEV1, FVC, and VC) from baseline (2) Change on thin-slice CT findings after EGFR-TKI treatment (3) Frequency and extent of adverse effect of EGFR-TKI (4) Response rate of EGFR-TKI	—

Countries

Japan

Contacts

Public ContactTeppei Yamaguchi

Fujita Health University School of Medicine Division of Respiratory Medicine and Clinical Allergy

yteppei@fujita-hu.ac.jp0562-93-9241

Outcome results